Big Pharma...increasingly believes that after years of being tarred by the controversial practices of some...there could be an economic benefit to engaging constructively with the world's poorest countries...and one way was by becoming better corporate citizens in emerging markets...Critics...point out that drugs companies are still bringing controversial cases against developing countries over patents...Yet, analysts believe...searching out new markets in rapidly growing parts of the world is in drugs companies' best interests. [refers to GlaxoSmithKline, Novartis, Novo Nordisk (part of Novo Group), Roche]